Article Text

Download PDFPDF
Journal club
VX-770, a CFTR potentiator, may have a potential clinical benefit in a subgroup of people with cystic fibrosis
  1. Sneh Shah
  1. Correspondence to Sneh Shah, ACCS CT1, Croydon University Hospital, 530 London Road, Croydon CR7 7YE, UK; sneh.shah{at}doctors.net.uk

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Cystic fibrosis (CF) is caused by mutations in the gene encoding the CFTR (CF transmembrane conductance regulator) protein, an epithelial ion channel. Some mutations, of which the G551D mutation is the most common (occurring in approximately 5% of people with CF), permit the defective CFTR protein to reach the epithelial …

View Full Text